Compare MIRM & STNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | STNE |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.4B |
| IPO Year | 2019 | 2018 |
| Metric | MIRM | STNE |
|---|---|---|
| Price | $100.65 | $17.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $102.64 | $17.50 |
| AVG Volume (30 Days) | 733.0K | ★ 5.7M |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $471,794,000.00 | ★ $2,670,485,228.00 |
| Revenue This Year | $55.91 | $15.38 |
| Revenue Next Year | $23.97 | $6.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.66 | 24.14 |
| 52 Week Low | $36.88 | $8.64 |
| 52 Week High | $105.74 | $19.95 |
| Indicator | MIRM | STNE |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 63.68 |
| Support Level | $97.49 | $15.85 |
| Resistance Level | $105.74 | $18.19 |
| Average True Range (ATR) | 3.71 | 0.79 |
| MACD | -0.79 | 0.17 |
| Stochastic Oscillator | 62.01 | 79.50 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
StoneCo Ltd is a provider of financial technology solutions. It serves MSMBs solutions, at fair prices, and provides the customer experience to help them manage their businesses and sell more. Its Stone Business Model combines end-to-end, cloud-based technology platforms; differentiated hyper-local and integrated distribution approaches; and white-glove, on-demand customer service. It has two segments Financial Services segment, which includes payments solutions, digital banking, credit, insurance solutions as well as the registry business. In the Software segment solution includes POS/ERP, TEF and QR Code gateways, reconciliation, CRM, OMS, e-commerce platform, engagement tool, ads solution, and marketplace hub. It generates the majority of its revenue from the Financial Services segment.